Literature DB >> 33879188

TWIST2 and the PPAR signaling pathway are important in the progression of nonalcoholic steatohepatitis.

Yanmei Zhang1,2, Xiaoxiao Ge1, Yongqing Li1, Bingyang Zhang1, Peijun Wang1, Mingju Hao1,3, Peng Gao4, Yueyi Zhao3, Tao Sun1,3, Sumei Lu5,6, Wanshan Ma7,8.   

Abstract

BACKGROUND: To investigate the roles of the transcription factors twist family bHLH transcription factor 1 (TWIST1), twist family bHLH transcription factor 2 (TWIST2), and peroxisome proliferator activated receptor gamma (PPARγ) in the progression of nonalcoholic steatohepatitis.
METHODS: The protein levels of TWIST1, TWIST2 and PPARγ were determined in the serum of nonalcoholic fatty liver disease (NAFLD) patients and healthy controls by enzyme-linked immunosorbent assay (ELISA). An in vivo model for fatty liver was established by feeding C57BL/6 J mice a high-fat diet (HFD). An in vitro model of steatosis was established by treating LO-2 cells with oleic acid (OA). RNA sequencing was performed on untreated and OA-treated LO-2 cells followed by TWIST1, TWIST2 and PPARγ gene mRNA levels analysis, Gene Ontology (GO) enrichment and pathway analysis.
RESULTS: The TWIST2 serum protein levels decreased significantly in all fatty liver groups (P < 0.05), while TWIST1 varied. TWIST2 tended to be lower in mice fed an HFD and was significantly lower at 3 months. Similarly, in the in vitro model, the TWIST2 protein level was downregulated significantly at 48 and 72 h after OA treatment. RNA sequencing of LO-2 cells showed an approximately 2.3-fold decrease in TWIST2, with no obvious change in TWIST1 and PPARγ. The PPAR signaling pathway was enriched, with 4 genes upregulated in OA-treated cells (P = 0.0018). The interleukin (IL)-17 and tumor necrosis factor (TNF) signaling pathways were enriched in OA-treated cells.
CONCLUSIONS: The results provide evidence that the TWIST2 and PPAR signaling pathways are important in NAFLD and shed light on a potential mechanism of steatosis.

Entities:  

Keywords:  Hepatocyte steatosis; High-fat diet; Nonalcoholic fatty liver disease; Peroxisome proliferator activated receptor gamma (PPARγ); TWIST family bHLH transcription factor 1 (TWIST1); TWIST family bHLH transcription factor 2 (TWIST2); The PPAR signaling pathway

Year:  2021        PMID: 33879188     DOI: 10.1186/s12944-021-01458-0

Source DB:  PubMed          Journal:  Lipids Health Dis        ISSN: 1476-511X            Impact factor:   3.876


  27 in total

1.  Evidence-based clinical practice guidelines for nonalcoholic fatty liver disease/nonalcoholic steatohepatitis.

Authors:  Sumio Watanabe; Etsuko Hashimoto; Kenichi Ikejima; Hirofumi Uto; Masafumi Ono; Yoshio Sumida; Masataka Seike; Yoshiyuki Takei; Tetsuo Takehara; Katsutoshi Tokushige; Atsushi Nakajima; Masashi Yoneda; Toshiji Saibara; Goshi Shiota; Isao Sakaida; Makoto Nakamuta; Toshihiko Mizuta; Hirohito Tsubouchi; Kentaro Sugano; Tooru Shimosegawa
Journal:  Hepatol Res       Date:  2015-04       Impact factor: 4.288

Review 2.  Evolution of inflammation in nonalcoholic fatty liver disease: the multiple parallel hits hypothesis.

Authors:  Herbert Tilg; Alexander R Moschen
Journal:  Hepatology       Date:  2010-11       Impact factor: 17.425

Review 3.  Biogenesis, secretion, and intercellular interactions of exosomes and other extracellular vesicles.

Authors:  Marina Colombo; Graça Raposo; Clotilde Théry
Journal:  Annu Rev Cell Dev Biol       Date:  2014-08-21       Impact factor: 13.827

Review 4.  Animal models of nonalcoholic fatty liver disease.

Authors:  Lionel Hebbard; Jacob George
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2010-11-30       Impact factor: 46.802

Review 5.  The epidemiology of non-alcoholic fatty liver disease.

Authors:  Stefano Bellentani
Journal:  Liver Int       Date:  2017-01       Impact factor: 5.828

Review 6.  Non-alcoholic fatty liver disease pathogenesis: the present and the future.

Authors:  S Petta; C Muratore; A Craxì
Journal:  Dig Liver Dis       Date:  2009-02-14       Impact factor: 4.088

7.  Relationship between non-alcoholic fatty liver disease, metabolic syndrome and insulin resistance in Korean adults: A cross-sectional study.

Authors:  Ji Young Kim; Choae Lee; Minsuk Oh; Jee-Aee Im; Ji-Won Lee; Sang Hui Chu; Hyangkyu Lee; Justin Y Jeon
Journal:  Clin Chim Acta       Date:  2016-03-25       Impact factor: 3.786

Review 8.  Molecular mechanisms and new treatment strategies for non-alcoholic steatohepatitis (NASH).

Authors:  Akinobu Takaki; Daisuke Kawai; Kazuhide Yamamoto
Journal:  Int J Mol Sci       Date:  2014-04-29       Impact factor: 5.923

Review 9.  Novel Molecular Mechanisms in the Development of Non-Alcoholic Steatohepatitis.

Authors:  Davide Povero; Ariel E Feldstein
Journal:  Diabetes Metab J       Date:  2016-02       Impact factor: 5.376

10.  Involvement of resistin-like molecule β in the development of methionine-choline deficient diet-induced non-alcoholic steatohepatitis in mice.

Authors:  Hirofumi Okubo; Akifumi Kushiyama; Hideyuki Sakoda; Yusuke Nakatsu; Masaki Iizuka; Naoyuki Taki; Midori Fujishiro; Toshiaki Fukushima; Hideaki Kamata; Akiko Nagamachi; Toshiya Inaba; Fusanori Nishimura; Hideki Katagiri; Takashi Asahara; Yasuto Yoshida; Osamu Chonan; Jeffery Encinas; Tomoichiro Asano
Journal:  Sci Rep       Date:  2016-01-28       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.